文献

J-GLOBAL ID：201802232840502733   整理番号：18A0135611

化学療法併用レジメンのナノ粒子送達は肺癌のマウスモデルにおける治療効果を改善する【Powered by NICT】

Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer

著者 (28件)： Tian Jing (School of Biological and Environmental Engineering, Tianjin Vocational Institute, Tianjin, PR China) ,  Tian Jing (Laboratory of Nano- and Translational Medicine, Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Tian Jing (Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Min Yuangzeng (Laboratory of Nano- and Translational Medicine, Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Min Yuangzeng (Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Rodgers Zachary (Laboratory of Nano- and Translational Medicine, Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Rodgers Zachary (Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Wan Xiaomeng (Division of Molecular Pharmaceutics, Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Qiu Hui (Laboratory of Nano- and Translational Medicine, Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Qiu Hui (Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Qiu Hui (Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China) ,  Mi Yu (Laboratory of Nano- and Translational Medicine, Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Mi Yu (Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Tian Xi (Laboratory of Nano- and Translational Medicine, Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Tian Xi (Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Wagner Kyle T. (Laboratory of Nano- and Translational Medicine, Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Wagner Kyle T. (Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Caster Joseph M. (Laboratory of Nano- and Translational Medicine, Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Caster Joseph M. (Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Qi Yanfei (Laboratory of Nano- and Translational Medicine, Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Qi Yanfei (Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Qi Yanfei (School of Public Health, Jilin University, Changchun, Jilin, China) ,  Roche Kyle (Laboratory of Nano- and Translational Medicine, Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Roche Kyle (Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Zhang Tian (Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA) ,  Cheng Jianjun (Department of Materials Science and Engineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA) ,  Wang Andrew Z. (Laboratory of Nano- and Translational Medicine, Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) ,  Wang Andrew Z. (Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA)
資料名： Nanomedicine: Nanotechnology, Biology, and Medicine  (Nanomedicine: Nanotechnology, Biology, and Medicine)
巻： 13  号： 3  ページ： 1301-1307  発行年： 2017年 
JST資料番号： W3138A  ISSN： 1549-9634  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： オランダ (NLD)  言語： 英語 (EN)

抄録/ポイント： シスプラチン(CP)とドセタキセル(DTX)の併用化学療法は種々の癌に対して有効である。しかし,併用療法は治療抵抗性を生成できる特異的薬物比への臨床応用,毒性の増加と腫瘍の不正確な曝露を複雑にする可能性のあるユニークな挑戦を提示した。単一ナノ粒子(NP)定式化の枠内で薬物共カプセル化は,これらの課題を克服し,さらにの組合せ治療指数を改善することができる。本報告では,CPPおよびDTXの両方を持つポリ(lactic-co-グリコール酸)-ポリ(エチレングリコール)(PLGA PEG)NPを定式化するためにCPプロドラッグ(CPP)戦略を採用した。二重負荷NPを選択CPPの構造に基づく薬物放出動力学とin vitro細胞毒性の違いを示した。さらに,両薬剤を含むNPは治療効果と遊離薬剤の組合わせにおけるin vivoでの有意な改善を示した。Copyright 2018 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【Powered by NICT】

シソーラス用語： *薬物療法 ,  併用療法 ,  プロドラッグ ,  シスプラチン ,  *ナノ粒子 ,  *肺腫瘍 ,  定式化 ,  毒性 ,  芳香族カルボン酸 ,  カルバミド酸エステル ,  酸素複素環化合物 ,  架橋化合物 ,  四環ジテルペン ,  カルボン酸エステル ,  ヒドロキシ酸 ,  ヒドロキシケトン ,  ポリオール
準シソーラス用語： 放出速度 ,  治療指数 ,  治療抵抗性 ,  多剤併用療法 ,  *臨床効果 ,  *レジメン , 【Automatic Indexing@JST】

著者キーワード (5件)： ドラッグデリバリー ,  PLGA-PEG ,  シスプラチンプロドラッグ ,  ドセタキセル ,  併用療法

分類 (2件)： 腫ようの実験的治療  (GE02040Y) ,  生物薬剤学(基礎)  (GY01021U)

物質索引 (1件)： ドセタキセル

タイトルに関連する用語 (8件)： 化学療法 ,  併用 ,  レジメン ,  ナノ粒子 ,  送達 ,  肺癌 ,  マウスモデル ,  治療効果